Newbury Pharmaceuticals
Newbury Pharmaceuticals is a Swedish pharmaceutical company focused on in-licensed prescription drugs, specialty medicines, and own-brand products. The company works through partnerships to register, commercialize, and distribute pharmaceuticals across the Nordic markets, while also serving selected international customers through indirect channels.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePrescription medicines acquired through licensing agreements and commercialized in Newbury's markets.
Specialty pharmaceutical products targeted at specific therapeutic or market niches.
Products marketed under Newbury's own brand names, built around licensed product rights.
Commercial and distribution activities for partners not directly represented in the Nordics.
Customers
Newbury sells to pharmaceutical buyers in the Nordic region and to international customers reached through indirect sales arrangements. Its customer base also includes partners that license product rights to Newbury and rely on the company for registration, market access, and commercialization. The business is built around serving patients through pharmacies, healthcare channels, and other pharmaceutical stakeholders via partner products.
Buy prescription and specialty medicines for patient use in the Nordic market.
License product rights to Newbury and use it to register and commercialize products in Scandinavia.
Purchase through indirect channels outside the Nordics where Newbury extends partner products.
Indirect beneficiaries of specialty drugs and own-brand medicines commercialized by Newbury.
Strategy
Newbury's strategy is to build a portfolio of licensed pharmaceutical products through partnerships rather than internal drug development. It aims to deepen its Nordic commercial platform, use local market knowledge to register and launch products efficiently, and extend selected products into additional markets through indirect distribution.
A broader portfolio increases commercial reach without requiring internal R&D.
Local registration and commercialization expertise is the core competitive advantage.
International channels diversify the customer base and broaden product monetization.
Geography
Newbury is anchored in the Nordic markets, where it focuses on building direct business and market expertise. Outside the Nordics, it pursues international sales through an indirect model, which broadens reach without requiring the same local operating footprint. The company has also noted exposure to the Middle East, where geopolitical disruption has affected freight, logistics, and the pace of business activity.
Risks
Newbury's business depends on third-party product rights, partner relationships, and access to regulated pharmaceutical markets, so supply, licensing, and market-access execution are central risks. The company also faces external exposure to trade policy changes, tariffs, and geopolitical disruption, which can raise logistics costs and slow international activity. As in the broader pharma distribution model, regulatory compliance, product concentration, and customer payment timing can materially affect results.
- Customer credit and collection riskImpact: HighLikelihood: High
The company disclosed delayed payments from international sales customers.
Exposure: Receivables and cash conversion
- Dependence on third-party product rightsImpact: HighLikelihood: Medium
The company does not develop its own drugs and must secure licensed products from partners.
Exposure: Portfolio availability and commercial continuity
- Regulatory and registration riskImpact: HighLikelihood: Low
Pharmaceutical commercialization depends on approvals, registrations, and local compliance.
Exposure: Nordic and international market access
- Geopolitical and logistics disruption in the Middle EastImpact: MediumLikelihood: High
The company disclosed slower business activity and higher freight/logistics costs in the region.
Exposure: International operations in the Middle East
- Trade policy and tariff changesImpact: MediumLikelihood: Low
Cross-border pharmaceutical distribution can be affected by new barriers or duties.
Exposure: International sourcing and sales
Accounting
Judgemental itemsCommercialization and indirect sales can create timing differences around delivery, acceptance, and invoicing.
Impact: Affects quarterly revenue comparability
The company disclosed delayed international customer payments and ongoing collection discussions.
Impact: Can affect reported assets and earnings
Balances linked to canceled pipeline products may be used for future acquisitions or require valuation review.
Impact: May influence asset carrying values
The parent recorded both a shareholder contribution and an equal write-down of subsidiary shares.
Impact: Can materially affect parent-company equity and profit
Option programs create non-cash compensation expense and potential dilution.
Impact: Affects operating costs and share count
Similar listed companies
Publicly listed companies with a comparable business focus.
Medivir
MVIR · Health Care
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases.
Nordicus Partners Corp
NORD · Services-Management Consulting Services
Nordicus Partners Corp is a U.S.-listed business accelerator and holding company focused on Nordic life sciences ventures.
Semnur Pharmaceuticals, Inc.
SMNR · Pharmaceutical Preparations
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
Novo Nordisk A/S
NVO · Pharmaceutical Preparations
Novo Nordisk A/S is a Denmark-based pharmaceutical company focused on medicines for diabetes, obesity, and other serious chronic diseases.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Last updated: 24/09/2026